Sanofi ADR (SNYy)

Currency in EUR
42.80
+1.80(+4.39%)
Closed·
Unusual trading volume
Fair Value
Day's Range
42.2042.80
52 wk Range
41.0055.00
Key Statistics
Bid/Ask
42.60 / 42.80
Prev. Close
42.8
Open
42.4
Day's Range
42.2-42.8
52 wk Range
41-55
Volume
503
Average Volume (3m)
164
1-Year Change
-8.94%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SNYy Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.

Sanofi ADR News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Sanofi ADR Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, yellow fever, and rabies vaccines. In addition, the company has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences to develop pivotal studies and clinical development program. Further, it has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop novel targeted protein degradation therapies; Denali Therapeutics Inc. to treat a range of systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for the discovery and development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab, as well as an strategic alliance with the Department of Health – Abu Dhabi for the development of global vaccines. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Compare SNYy to Peers and Sector

Metrics to compare
SNYy
Peers
Sector
Relationship
P/E Ratio
0.0x9.3x−0.5x
PEG Ratio
0.000.100.00
Price/Book
0.0x1.3x2.6x
Price / LTM Sales
0.0x2.2x3.2x
Upside (Analyst Target)
0.0%23.3%41.9%
Fair Value Upside
Unlock8.4%4.3%Unlock

Earnings

Latest Release
-
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

SNYy Income Statement

People Also Watch

419.39
LMT
+2.11%
70.03
NVO
+4.87%
73.00
AZN
+3.58%
73.27
MRVL
+1.78%

FAQ

What Stock Exchange Does Sanofi ADR Trade On?

Sanofi ADR is listed and trades on the Frankfurt Stock Exchange stock exchange.

What Is the Stock Symbol for Sanofi ADR?

The stock symbol for Sanofi ADR is "SNYy."

What Is the Sanofi ADR Market Cap?

As of today, Sanofi ADR market cap is 103.12B.

What Is Sanofi ADR's Earnings Per Share (TTM)?

The Sanofi ADR EPS (TTM) is 0.00.

From a Technical Analysis Perspective, Is SNYy a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Sanofi ADR Stock Split?

Sanofi ADR has split 0 times.

What is the current trading status of Sanofi ADR (SNYy)?

As of 24 Jul 2025, Sanofi ADR (SNYy) is trading at a price of 42.80, with a previous close of 42.80. The stock has fluctuated within a day range of 42.20 to 42.80, while its 52-week range spans from 41.00 to 55.00.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.